Keele Research Repository

Article

Sumpter, NA, Takei, R, Cadzow, M, Topless, RKG, Phipps-Green, AJ, Murphy, R, de Zoysa, J, Watson, H, Qasim, M, Lupi, AS, Abhishek, A, Andrés, M, Crișan, TO, Doherty, M, Jacobsson, L, Janssen, M, Jansen, TL, Joosten, LAB, Kapetanovic, M, Lioté, F, Matsuo, H, McCarthy, GM, Perez-Ruiz, F, Riches, P, Richette, P, Roddy, E ORCID: https://orcid.org/0000-0002-8954-7082, Stiburkova, B, So, A, Tausche, A-K, Torres, RJ, Uhlig, T, Major, TJ, Stamp, LK, Dalbeth, N, Choi, HK, Vazquez, AI, Leask, MP, Reynolds, RJ and Merriman, TR (2022) Association of Gout Polygenic Risk Score with Age at Disease Onset and Tophaceous Disease in European and Polynesian Men with Gout. Arthritis & Rheumatology.

Pan, S, Tsakok, T, Dand, N, Lonsdale, DO, Loeff, FC, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, CEM, Reynolds, NJ, Barker, J, Warren, RB, David Burden, A, Rispens, T, Standing, JF, Smith, CH and Study Group, the BSTOP Study Group, the PSORT Consortium, BADBIR (2020) Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 13 (2). 400 - 409.

Dand, N, Duckworth, M, Baudry, D, Russell, A, Curtis, CJ, Lee, SH, Evans, I, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Alsharqi, A, Becher, G, Burden, AD, Goodwin, RG, McKenna, K, Murphy, R, Perera, GK, Rotarescu, R, Wahie, S, Wright, A, Reynolds, NJ, Warren, RB, Griffiths, CEM, Smith, CH, Simpson, MA, Barker, JN, Study Group, BADBIR, Study Group, BSTOP and Consortium, PSORT (2018) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143 (6). 2120 - 2130.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.